Christian Jung

Christian joined SV Health Managers in 2019. He is a Partner in the Dementia Discovery Fund (DDF) and currently represents the fund on the Boards of Amphista Therapeutics Ltd., LoQus23 Therapeutics Ltd. and Transine Therapeutics Ltd. Prior to joining SV, Christian held roles with Wellington Partners Life Sciences and High-Tech Gründerfonds, Europe’s leading seed fund with € 1.3bn under management. There, Christian structured and completed the seed- and early-stage investments in nine life sciences companies, including Amal Therapeutics SA (acquired by Boehringer Ingelheim in 2019 for up to € 325m), Cunesoft GmbH (acquired by Phlexglobal in 2020 for an undisclosed amount) and Rigontec GmbH (acquired by MSD in 2017 for up to €464m).

Christian was awarded a PhD with distinction in Medical Science and Technology for his work on patient-specific induced pluripotent stem cells and obtained his MSc degree in Molecular Biotechnology, both from the Technical University of Munich. The key articles generated in the context of his PhD were published in the New England Journal of Medicine, EMBO Molecular Medicine and FASEB Journal and have so far been cited more than 1,000 times.